61 Kazia Theraputics Limited Annual Report 2023 Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports Note 12. Trade & other receivables - non-current Consolidated 2023 2022 $ $ Non-current assets GBM Agile deposit - 7,257,947 Corporate credit card deposit 42,922 42,923 42,922 7,300,870 Note 13. Other assets Consolidated 2023 2022 $ $ Current assets Prepayments 1,632,472 1,997,205 Note 14. Intangibles Consolidated 2023 2022 restated $ $ Non-current assets Licensing agreement - paxalisib 16,407,788 16,407,788 Less: Accumulated amortisation (7,250,728) (6,166,344) 9,157,060 10,241,444 Licensing agreement - EVT-801 9,813,362 9,813,362 Less: Accumulated amortisation (1,700,990) (915,914) 8,112,372 8,897,448 17,269,432 19,138,892 Reconciliations Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below: EVT801 licensing agreement * Paxalisib licensing agreement Total Consolidated $ $ $ Balance at 1 July 2021 as restated * 9,682,517 11,325,795 21,008,312 Amortisation expense (785,069) (1,084,351) (1,869,420) Balance at 30 June 2022 8,897,448 10,241,444 19,138,892 Amortisation expense (785,076) (1,084,384) (1,869,460) Balance at 30 June 2023 8,112,372 9,157,060 17,269,432
RkJQdWJsaXNoZXIy MjE2NDg3